Patents by Inventor David F. Erkoboni
David F. Erkoboni has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200129438Abstract: The present application discloses a finished pharmaceutical dosage form comprising a low dose/high potency active pharmaceutical ingredient and one or more excipients. The active pharmaceutical ingredient in the present application has been blended and subsequently milled with at least one excipient before preparing the finished pharmaceutical dosage form. The disclosed finished dosage form promotes content uniformity and acceptable and reproducible dissolution rate and extent. Finished dosage forms of the present invention may comprise any active pharmaceutical ingredient; however, low solubility and/or high potency active pharmaceutical ingredients will particularly benefit. Among the low solubility and/or high potency active pharmaceutical ingredients, those with needle-like structures are even more particularly well suited for incorporation into the disclosed finished dosage forms.Type: ApplicationFiled: October 31, 2018Publication date: April 30, 2020Applicant: Edenbridge Pharmaceuticals, LLCInventor: David F. Erkoboni
-
Patent number: 10213388Abstract: Aspects of the present invention are directed to abuse resistant oral dosage forms comprising a compressed microtablet that is coated with a water-retardant polymer. Additional aspects of the present invention are directed to an oral dosage form comprising an opioid agonist and at least one compressed microtablet coated with a water retardant polymer. The compressed microtablet may comprise an opioid antagonist.Type: GrantFiled: May 18, 2015Date of Patent: February 26, 2019Assignee: Elite Laboratories, Inc.Inventors: Christopher C. Dick, David F. Erkoboni, Charanjit R. Behl, Gary Bubb
-
Publication number: 20160008777Abstract: A kit which is useful in the preparation of a compounded pharmaceutical product is provided. A method for using such a kit to make a compounded pharmaceutical product, and a compounded pharmaceutical product are also provided. Further provided is an apparatus for use in making a compounded pharmaceutical product.Type: ApplicationFiled: July 8, 2015Publication date: January 14, 2016Inventors: Kunal PATEL, David F. ERKOBONI, Snehal PATEL, Piushbhai J. PATEL, Lyndsey Marie SZEM, Jeimy RODRIGUEZ
-
Publication number: 20150250732Abstract: Aspects of the present invention are directed to abuse resistant oral dosage forms comprising a compressed microtablet that is coated with a water-retardant polymer. Additional aspects of the present invention are directed to an oral dosage form comprising an opioid agonist and at least one compressed microtablet coated with a water retardant polymer. The compressed microtablet may comprise an opioid antagonist.Type: ApplicationFiled: May 18, 2015Publication date: September 10, 2015Inventors: Christopher C. Dick, David F. Erkoboni, Charanjit R. Behl, Gary Bubb
-
Patent number: 9056054Abstract: Aspects of the present invention are directed to abuse resistant oral dosage forms comprising a compressed microtablet that is coated with a water-retardant polymer. Additional aspects of the present invention are directed to an oral dosage form comprising an opioid agonist and at least one compressed microtablet coated with a water retardant polymer. The compressed microtablet may comprise an opioid antagonist.Type: GrantFiled: June 25, 2010Date of Patent: June 16, 2015Assignee: Elite Laboratories, Inc.Inventors: Christopher C. Dick, David F. Erkoboni, Charanjit R. Behl, Gary Bubb
-
Publication number: 20130084333Abstract: Aspects of the present invention are directed to abuse resistant oral dosage forms comprising a compressed microtablet that is coated with a water-retardant polymer. Additional aspects of the present invention are directed to an oral dosage form comprising an opioid agonist and at least one compressed microtablet coated with a water retardant polymer. The compressed microtablet may comprise an opioid antagonist.Type: ApplicationFiled: June 25, 2010Publication date: April 4, 2013Applicant: ELITE LABORATORIES, INCInventors: Christopher C. Dick, David F. Erkoboni, Charanjit R. Behl, Gary Bubb
-
Publication number: 20120189693Abstract: Aspects of the present invention are directed to oral dosage forms comprising a compressed microtablet, wherein said microtablet has a major dimension that is between about 0.25 mm and about 1.0 mm and comprises at least about 0.01 weight percent of at least one pharmaceutically active agent that is distributed substantially throughout said microtablet. Additional aspects of the present invention are directed to methods for producing compressed microtablets having a major dimension that is between about 0.25 mm and about 1.0 mm.Type: ApplicationFiled: June 25, 2010Publication date: July 26, 2012Applicant: Elite Laboratories, Inc.Inventors: Christopher C. Dick, David F. Erkoboni, Charanjit R. Behl, Gary Bubb
-
Publication number: 20090263478Abstract: Disclosed are amorphous carvedilol salt forms, controlled-release carvedilol compositions, and methods of preparing the forms and compositions.Type: ApplicationFiled: July 9, 2009Publication date: October 22, 2009Inventors: Kristin Arnold, David F. Erkoboni, Rakeshkumar K. Lad, Siva Rama K. Nutalapati, Zhongshui Yu
-
Publication number: 20090028935Abstract: Disclosed are amorphous carvedilol salt forms, controlled-release carvedilol compositions, and methods of preparing the forms and compositions.Type: ApplicationFiled: July 31, 2008Publication date: January 29, 2009Inventors: Kristin Arnold, David F. Erkoboni
-
Publication number: 20080299189Abstract: The present invention relates to a multiphase release oral pharmaceutical formulation having a dopamine agonist as an active ingredient. The multiphase composition comprises at least two different release components. The invention relates to controlled release pharmaceutical compositions of pramipexole or a pharmaceutically acceptable salt thereof for once-daily administration.Type: ApplicationFiled: May 23, 2008Publication date: December 4, 2008Applicant: DRUGTECH CORPORATIONInventors: Jonathan David Bortz, Michael Grimshaw, David F. Erkoboni
-
Publication number: 20080292695Abstract: Disclosed are amorphous carvedilol salt forms, controlled-release carvedilol compositions, and methods of preparing the forms and compositions.Type: ApplicationFiled: December 3, 2007Publication date: November 27, 2008Inventors: Kristin Arnold, E. Brendan Magrab, David F. Erkoboni, Zhongshui Yu, Siva Rama K. Nutalapati, Rakeshkumar K. Lad
-
Publication number: 20080139655Abstract: A pharmaceutical composition comprising levodopa is provided that, when administered in a unit dosage amount of levodopa of about 100 to about 500 mg at a dosage interval of about 6 to about 24 hours, exhibits a sufficiently long release period and a sufficiently long residence time in the upper gastrointestinal tract to provide a trough concentration of levodopa in plasma of the subject that is not lower than a minimum threshold concentration below which adverse motor effects are observed in the subject. A method for treating Parkinson's disease in a subject is also provided, comprising orally administering such a composition to the subject in a unit dosage amount of levodopa of about 50 to about 1000 mg at a dosage interval of about 3 to about 24 hours.Type: ApplicationFiled: September 5, 2007Publication date: June 12, 2008Applicant: DrugTech CorporationInventors: Jonathan Bortz, Michael Grimshaw, David F. Erkoboni, Michael F. Dickus
-
Patent number: 6858725Abstract: Granulation of microcrystalline cellulose with a granulating fluid consisting of water and a water-miscible, volatile, polar organic solvent yields porous granules which are comprised of particles that are larger than the ungranulated microcrystalline cellulose. This granulated microcrystalline cellulose is capable of cushioning controlled release particles and barrier coated particles from the compression forces used in tableting, thereby maintaining the physical integrity of the components of the tablet.Type: GrantFiled: November 9, 2000Date of Patent: February 22, 2005Assignee: R.P. Scherer Technologies, Inc.Inventors: Ronald S. Vladyka, Jr., David F. Erkoboni, Christopher A. Sweriduk
-
Publication number: 20040213839Abstract: The present invention provides methods and compositions for reducing the perception of poor-tasting pharmaceutically active agents in the oral cavity. The invention provides particles containing one or more pharmaceutically active agents, flavorants and cellulosic materials, as well as methods for making same and for incorporating same into pharmaceutical dosage forms. In certain embodiments, the particles have a diameter of up to about 1000 micrometers and include the pharmaceutically active agent, a flavorant, and at least one cellulosic material that is microcrystalline cellulose, microcrystalline cellulose coprocessed with a hydrocolloid, or any combination thereof, individually or in admixture with a hydrocolloid.Type: ApplicationFiled: May 28, 2004Publication date: October 28, 2004Inventors: Andrew Favara, David F. Erkoboni
-
Publication number: 20040081701Abstract: The present invention provides a method for preparing a spray-dried, compressible granular formulation for preparing pharmaceutical tablets in which essentially water-insoluble, acidic, amphoteric, and basic pharmaceutically active agents are converted to more water-soluble salts which are granulated with hydrolyzed cellulose, drug-containing slurries, the resulting granulations, capsules containing granulations, and pharmaceutical tablets compressed from such granules. In these formulations there is employed from 1% to 85% by weight of the pharmaceutically active agent in its salt form, from 5% to 99% of hydrolyzed cellulose, based on the dry weight of the granulation, and optionally, conventional granulation and/or tableting additives such as surfactants, disintegrants, and antiadherents/flow aids. Said tablets have significantly increased dissolution of the pharmaceutically active agent at the pH of the gastrointestinal tract in comparison with the unconverted free pharmaceutically active agent.Type: ApplicationFiled: June 9, 2003Publication date: April 29, 2004Inventors: David F. Erkoboni, Ronald S. Vladyka, Christopher A. Sweriduk, Andrew J. Favara
-
Patent number: 6596312Abstract: The present invention provides a method for preparing a spray-dried, compressible granular formulation for preparing pharmaceutical tablets in which essentially water-insoluble, acidic, amphoteric, and basic pharmaceutically active agents are converted to more water-soluble salts which are granulated with hydrolyzed cellulose, drug-containing slurries, the resulting granulations, capsules containing granulations, and pharmaceutical tablets compressed from such granules. In these formulations there is employed from 1% to 85% by weight of the pharmaceutically active agent and its salt form, from 5% to 99% of hydrolyzed cellulose, based on the dry weight of the granulation, and optionally, conventional granulation and/or tableting additives such as surfactants, disintegrants, and antiadherents/flow aids. Said tablets have significantly increased dissolution of the pharmaceutically active agent at the pH of the gastrointestinal tract in comparison with the unconverted free pharmaceutically active agent.Type: GrantFiled: September 26, 2000Date of Patent: July 22, 2003Assignee: R.P. Scherer Technologies, Inc.Inventors: David F. Erkoboni, Ronald S. Vladyka, Jr., Christopher A. Sweriduk, Andrew J. Favara
-
Publication number: 20030055107Abstract: A pharmaceutical composition comprising a pharmaceutically active agent and a salt of said pharmaceutically active agent with the proviso that said composition does not contain hydrolyzed cellulose, wherein said pharmaceutical active agent is a weak acid or weak base. The present invention is also directed to a new ibuprofen form having, when potassium is present in said form as a counter ion, an IR peak at 1706 cm−1 shifted and broadened in absorbance relative to racemic ibuprofen free acid, the form's characteristic absorbance profile from 1000 to 650 cm−1 and broadened in absorbance relative to racemic ibuprofen free acid, the form's characteristic absorbance profile from 1000 to 650 cm−1 and D-spacings of 21.1, 7.1, and 3.4 Å by X-ray diffraction.Type: ApplicationFiled: March 27, 2002Publication date: March 20, 2003Inventors: Xinmin Samuel Xu, David F. Erkoboni, David B. Lebo
-
Patent number: 6511681Abstract: A formulation of a sparingly water-soluble, crystalline pharmaceutically active agent wherein the active agent is converted to and stabilized in its amorphous form as a solid solution of a normally hydrophobic vehicle is described. The amorphous state is stabilized by the composition of the formulation, providing long shelf life of the improved composition. This stabilized formulation also provides increased solubility and bioavailability of the active agent. Solutions of the active agent are stabilized by the composition, preventing recrystallization and precipitation of the less soluble, crystalline form of the active agent from aqueous solutions thereof.Type: GrantFiled: June 21, 2001Date of Patent: January 28, 2003Assignee: R.P. Scherer Technologies, Inc.Inventors: Ronald S. Vladyka, Jr., David F. Erkoboni, Pamela R. Stergios
-
Patent number: 6497905Abstract: A formulation of a sparingly water-soluble, crystalline pharmaceutically active agent wherein the active agent is converted to and stabilized in its amorphous form as a solid solution of a normally hydrophobic vehicle is described. The amorphous state is stabilized by the composition of the formulation, providing long shelf life of the improved composition. This stabilized formulation also provides increased solubility and bioavailability of the active agent. Solutions of the active agent are stabilized by the composition, preventing recrystallization and precipitation of the less soluble, crystalline form of the active agent from aqueous solutions thereof.Type: GrantFiled: March 20, 2000Date of Patent: December 24, 2002Assignee: R.P. Scherer Technologies, Inc.Inventors: Ronald S. Vladyka, Jr., David F. Erkoboni, Pamela R. Stergios
-
Patent number: 6379707Abstract: A formulation of a sparingly water-soluble, crystalline pharmaceutically active agent wherein the active agent is converted to and stabilized in its amorphous form as a solid solution of a normally hydrophobic vehicle is described. The amorphous state is stabilized by the composition of the formulation, providing long shelf life of the improved composition. This stabilized formulation also provides increased solubility and bioavailability of the active agent. Solutions of the active agent are stabilized by the composition, preventing recrystallization and precipitation of the less soluble, crystalline form of the active agent from aqueous solutions thereof.Type: GrantFiled: June 21, 2001Date of Patent: April 30, 2002Assignee: FMC CorporationInventors: Ronald S. Vladyka, Jr., David F. Erkoboni, Pamela R. Stergios